IRCT20200623047902N13已完成未知
Bioequivalence Study of Azithromycin 500 mg tablet manufactured by Sanamed company versus the originator brand in healthy volunteers
Sanamed pharma company0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-28)
- •Informed consent
- •Age (18-55 years old)
排除标准
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcohol and drug addiction
- •History of allergy to Azithromycin
研究者
相似试验
已完成
Unknown
Bioequivalence evaluation of Azithromycin Tablet 100 mg of Mahban Pharmaceutical companyIRCT20200625047913N10Hezareh Sevom Futuristic Pharmacist24
已完成
不适用
Bioequivalence study of Azithromycin 200 mg/5mL powder for oral suspension in healthy Thai volunteer under fasting conditioTCTR20180109003All Research Co., Ltd.42
已完成
不适用
Bioequivalence study of Azithromycin 250 mgIRCT20200623047902N8Sanamed pharma company24
尚未招募
Unknown
In-vivo Bioequivalence Study of Azithromycin 500 mg Capsules of The Test Drug (ZITHROSAD 500 mg Cap., Sajjad Darou, Iran)IRCT20200105046010N107Sajad darou shargh24
尚未招募
Unknown
Bioequivalence evaluation of Azithromycin Capsule 500 mg of Mahban Pharmaceutical companyIRCT20200625047913N15Hezareh Sevom Futuristic Pharmacist24